Drug Development
Disc Medicine’s leadership tried to express optimism that its rare disease therapy bitopertin can be approved based on a Phase 3 trial set to begin shortly. However, analysts are worried that the protocol was developed with former FDA leaders.
FEATURED STORIES
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Finally, Pfizer has submitted the request to FDA to grant emergency use status to their vaccine for children. Here’s everything you should know about the vaccine.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
In a new “Measuring the Return from Pharmaceutical Innovation” report by Deloitte’s Center for Health Solutions, returns from R&D innovation are up by 7% across the industry.
Regeneron and Sanofi’s anti-inflammatory drug Dupixent has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
Pfizer announced that Dr. William Pao, M.D., Ph.D., will take on the role of executive vice president and chief development officer as of March 21.
Microbiologics, Inc. commemorated its 50th anniversary in 2021 by playing a key role in helping the world manage the COVID-19 pandemic.
Recent FDA approval of ViiV Healthcare’s HIV treatment Cabenuva reduced dosing to once every two months.
OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.